CONBRIZA

البلد: إسرائيل

اللغة: الإنجليزية

المصدر: Ministry of Health

العنصر النشط:

BAZEDOXIFENE AS ACETATE 20 MG

متاح من:

NEOPHARM LTD

ATC رمز:

G03XC02

الشكل الصيدلاني:

COATED TABLETS

طريقة التعاطي:

PER OS

المصنعة من قبل:

PFIZER IRELAND PHARMACEUTICALS

المجموعة العلاجية:

BAZEDOXIFENE

الخصائص العلاجية:

CONBRIZA is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. When determining the choice of CONBRIZA or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefit

تاريخ الترخيص:

2013-04-01